Video

Liver Cancer Updates

Author(s):

Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer CenterJaffer A. Ajani, MD, MD Anderson Cancer Center

Experts who treat gastrointestinal malignancies discuss the appropriateness for lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma following the release of phase 1b data presented at the ASCO 2020 Virtual Meeting.

Data from an early-phase study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma is discussed. (ClinicalTrials.gov Identifier: NCT03006926)

Related Videos
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Olivia Aranha, MD, PhD
Michael Iglesia, MD, PhD
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Arndt Vogel, MD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Haeseong Park, MD, MPH
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO
Related Content
Haibo Qiu, MD
June 4th 2024

Olverembatinib Demonstrates Early Activity, Tolerability in SDH-deficient GIST

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Arndt Vogel, MD
June 2nd 2024

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

Jens Hoeppner, FAChirg, FACS, MD
June 2nd 2024

Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer

FDA
May 31st 2024

FDA Accepts BLA Resubmission for Zolbetuximab in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma